Blog
RSS FeedPosted by Michael Wonder on 02 Dec 2022
Tezepelumab for the treatment of patients with severe asthma
2 December 2022 - The Department of Health and Social Care has asked NICE to produce guidance on the use of ...
Posted by Michael Wonder on 01 Dec 2022
Lenvatinib mesylate in combination with pembrolizumab for the first-line treatment of patients with advanced renal cell carcinoma
30 November 2022 - The Department of Health and Social Care has asked NICE to produce guidance on the use of ...
Posted by Michael Wonder on 01 Dec 2022
Aurinia announces the Great Britain marketing authorisation of Lupkynis (voclosporin) for the treatment of lupus nephritis
30 November 2022 - MHRA Approval follows European Commission marketing authorisation of Lupkynis to treat adults with active lupus nephritis in ...
Posted by Michael Wonder on 01 Dec 2022
Cemiplimab for the first-line treatment of patients wth advanced or metastatic PD-L1 positive non-small-cell lung cancer
1 December 2022 - The Department of Health and Social Care has asked NICE to produce guidance on the use of ...
Posted by Michael Wonder on 30 Nov 2022
Ripretinib for the treatment of patients with an advanced gastro-intestinal stromal tumour after three or more therapies
30 November 2022 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 29 Nov 2022
Mepolizumab for the treatment of patients with severe chronic rhinosinusitis with nasal polyps
29 November 2022 - The Department of Health and Social Care has asked NICE to produce guidance on the use of ...
Posted by Michael Wonder on 29 Nov 2022
Leo Pharma’s Adtralza approved by MHRA, EC for adolescent atopic dermatitis
29 November 2022 - The MHRA and the European Commission have approved a change to the terms of the marketing ...
Posted by Michael Wonder on 29 Nov 2022
NICE’s new methods: putting innovation first, but at what cost?
28 November 2022 - Traditionally the gatekeeper to the NHS, NICE has increasingly reoriented its role towards facilitating access to innovative ...
Posted by Michael Wonder on 29 Nov 2022
Voclosporin with immunosuppressives for the treatment of patients with lupus nephritis
29 November 2022 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 29 Nov 2022
Mepolizumab for the treatment of patients with severe hypereosinophilic syndrome
29 November 2022 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 28 Nov 2022
Bayer’s Nubeqa receives MHRA approval to treat metastatic prostate cancer
28 November 2022 - The treatment will be made available immediately through an early access deal with NHS England. ...
Posted by Michael Wonder on 28 Nov 2022
Joint statement: NICE and SMC/HIS collaboration
25 November 2022 - NICE and SMC/HIS collaboration on the health technology appraisal of tixagevimab–cilgavimab (Evusheld) for preventing COVID-19. ...
Posted by Michael Wonder on 28 Nov 2022
NICE recommends Rinvoq (upadacitinib) as treatment option for moderately to severely active ulcerative colitis in adults
25 November 2022 - Publication of positive Final Draft Guidance from NICE is supported by data from three clinical studies that ...
Posted by Michael Wonder on 25 Nov 2022
Junshi Biosciences announces submission of a marketing authorisation application for toripalimab to the UK MHRA
24 November 2022 - Second marketing authorisation application submission in Europe reflects toripalimab’s steady yet speedy progress towards global commercialisation. ...
Posted by Michael Wonder on 24 Nov 2022
New life-extending treatment for rare forms of advanced gastro-oesophageal cancer recommended by NICE
24 November 2022 - Around 3,000 people could be eligible for a new life-extending combination therapy to treat rare forms of ...